NOVO-B.CO - Novo Nordisk A/S

Copenhagen - Copenhagen Real Time Price. Currency in DKK
308.30
+1.50 (+0.49%)
At close: 4:59PM CEST
Stock chart is not supported by your current browser
Previous Close306.80
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range304.05 - 310.10
52 Week Range260.20 - 354.80
Volume1,811,692
Avg. Volume2,602,811
Market Cap747.569B
Beta0.59
PE Ratio (TTM)19.61
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • We have a policy of not taking list price increases of ab...
    CNBC Videos21 days ago

    We have a policy of not taking list price increases of ab...

    Lars Fruergaard speaks about earnings and his company's U.S. business amid changing regulation.

  • Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
    Bloomberg Video3 months ago

    Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices

    Mar.02 -- Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets."

  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zacks5 days ago

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • Reuters9 days ago

    M&A shakes up European shares as bid targets IWG, EDP soar

    European shares edged down in early deals on Monday after a strong run of weekly gains, while dealmaking livened up trading with Britain's IWG and Portugal's EDP both surging higher on takeover offers. ...

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of NOVO B.CO earnings conference call or presentation 2-May-18 11:00am GMT

    Q1 2018 Novo Nordisk A/S Earnings Call

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of NOVO B.CO earnings conference call or presentation 3-May-18 12:15pm GMT

    Q1 2018 Novo Nordisk A/S Earnings Presentation

  • Novo Nordisk Fights Payer Pressure With New Meds
    Motley Fool15 days ago

    Novo Nordisk Fights Payer Pressure With New Meds

    Sales of older medications are on the decline, but newer medications helped the revenue line grow at constant exchange rates.

  • Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?
    Simply Wall St.15 days ago

    Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?

    Novo Nordisk A/S (NYSE:NVO) trades with a trailing P/E of 18.9x, which is lower than the industry average of 23.5x. While NVO might seem like an attractive stock to buy,Read More...

  • Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript
    Motley Fool20 days ago

    Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending March 31, 2018.

  • Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
    Zacks21 days ago

    Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

    Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

  • Reuters21 days ago

    Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook

    Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast. Operating profit fell 8 percent to 12.4 billion Danish crowns (1.5 billion pounds) in the January to March quarter compared with a year ago, hit by the depreciation of the U.S. dollar, but beat an average 11.8 billion crown forecast in a Reuters poll of analysts. With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once-weekly injection and tablet version of its semaglutide drug.

  • The Wall Street Journal27 days ago

    [$$] BP Appoints New Chairman

    BP has appointed Helge Lund to succeed Carl-Henric Svanberg as company chairman from the beginning of 2019.

  • Novo Nordisk Obtains Licence for Sickle Cell Disease Program
    Zacks2 months ago

    Novo Nordisk Obtains Licence for Sickle Cell Disease Program

    Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

  • Reuters2 months ago

    Novo Nordisk buys blood drug licence to boost anaemic biopharma business

    Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.

  • These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
    Investor's Business Daily2 months ago

    These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

    A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.

  • Reuters2 months ago

    Drugmaker Novo Nordisk looks to former oil boss to energise M&A

    Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.

  • Novo Nordisk Poised on Strong Pipeline Amid Competition
    Zacks2 months ago

    Novo Nordisk Poised on Strong Pipeline Amid Competition

    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.

  • Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
    Zacks2 months ago

    Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

    Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

  • Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
    Bloomberg3 months ago

    Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices

    Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets." (Source: Bloomberg)

  • Reuters3 months ago

    Novo Holdings launches $165 million 'superbug' drug venture fund

    A $165 million (£119 million) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines. Backed by Novo Holdings, which has big stakes in Danish drugmaker Novo Nordisk and enzymes specialist Novozymes, the new Repair Impact Fund will invest $20-40 million a year over three to five years in about 20 projects in Europe and the United States. Novo said on Wednesday its new fund would invest in start-ups, early-stage companies and corporate spin-outs, either as the sole investor or in a syndicate.

  • Reuters3 months ago

    Novo Nordisk successfully kicks off final-stage trials for first diabetes pill

    The world's largest diabetes drugmaker Novo Nordisk on Thursday presented the first successful data from a final-stage study for a pill it hopes will transform the diabetes market. The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure has been mounting in a crowded market targeting the world's 450 million diabetics. Novo Nordisk said the first of 10 phase III trials were successful in its primary objective by demonstrating "significant and superior" improvements in long-term blood sugar compared to a placebo.

  • Reuters3 months ago

    Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

    Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.

  • The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
    Zacks3 months ago

    The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

    The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal